| First Author | Xu X | Year | 2023 |
| Journal | Cell Biol Int | Volume | 47 |
| Issue | 6 | Pages | 1126-1135 |
| PubMed ID | 36841942 | Mgi Jnum | J:344812 |
| Mgi Id | MGI:7579472 | Doi | 10.1002/cbin.12006 |
| Citation | Xu X, et al. (2023) TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF-kB/NLRP3 inflammasome pathway. Cell Biol Int 47(6):1126-1135 |
| abstractText | Diabetic nephropathy (DN) is one of the most common complications of diabetes. Gradual loss of podocytes is a sign of DN and pyroptosis mechanistically correlates with podocyte injury in DN; however, the mechanism(s) involved remain unknown. Here we reveal that TRIM29 is overexpressed in high glucose (HG)-treated murine podocytes cells and that TRIM29 silencing significantly inhibits podocyte damage due to HG treatment, as evidenced by lower desmin expression and greater nephrin expression. Additionally, flow cytometry analysis showed that TRIM29 silencing significantly inhibited HG treatment-induced pyroptosis, which was confirmed by immunoblotting for NLRP3, active Caspase-1, GSDMD-N, and phosphorylated NF-kappaB-p65. Conversely, overexpression of TRIM29 could trigger pyroptosis that was attenuated by NF-kappaB inhibition, indicating that TRIM29 promotes pyroptosis through the NF-kappaB pathway. Mechanistic studies revealed that TRIM29 interacts with IkappaBalpha to mediate its ubiquitination-dependent degradation, which in turn leads to NF-kappaB activation. Taken together, our data demonstrate that TRIM29 can promote podocyte pyroptosis by activating the NF-kappaB/NLRP3 pathway. Thus, TRIM29 represents a potentially novel therapeutic target that may also be clinically relevant in the management of DN. |
